• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

VV116 noninferior to nirmatrelvir-ritonavir for sustained recovery in COVID-19 patients

byAndrew LeeandKiera Liblik
February 14, 2023
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. VV116 is noninferior compared to nirmatrelvir-ritonavir for achieving sustained recovery in mild-to-moderate coronavirus disease 2019 (COVID-19) cases. 

2. Participants in the VV116 group experienced fewer adverse events compared to participants in the nirmatrelvir-ritonavir group within the 28-day study period.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Nirmatrelvir-ritonavir is an antiviral treatment that received widespread authorization for emergency use for the treatment of COVID-19. VV116 is a deuterated remdesivir hydrobromide shown to have potent activity against SARS-CoV-2. In this study comparing VV116 to nirmatrelvir-ritonavir for the treatment of COVID-19, sustained clinical recovery occurred at similar rates in both the nirmatrelvir-ritonavir and VV116 groups. No participants died or progressed to severe COVID-19 by the end of the study. The median time from randomization to sustain resolution of COVID-19-related symptoms was the same in both groups. The time to the first negative SARS-CoV-2 test was similar between groups. Fewer participants in the VV116 group experienced adverse events than in the nirmatrelvir-ritonavir group. None of the three serious adverse events were attributed to the assigned treatment. The most common adverse events were dysgeusia, hypertriglyceridemia, and hyperlipidemia. The strength of this study is that the patient population represented the general population with regard to vaccination status, and the efficacy was similar in subgroup analyses of both vaccinated and unvaccinated populations. A limitation of the study is that the patient population was likely infected with the omicron variant, which may limit the application of these treatments to this specific variant.

Click to read the study in NEJM

Relevant Reading: Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19

RELATED REPORTS

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

2 Minute Medicine Rewind July 7, 2025

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

In-Depth [randomized controlled trial]: This multicenter, observer-blinded, randomized controlled trial examined the efficacy of oral VV116 compared to oral nirmatrelvir-ritonavir for symptomatic participants at high risk for progression to severe COVID-19. The inclusion criteria were adults age 18 years of age or older, mild-to-moderate COVID-19, positive SARS-CoV-2 reverse-transcriptase-polymerase-chain-reaction test, and at least one risk factor for severe COVID-19. A total of 822 participants were randomized into the study, with 411 participants in each treatment group. Sustained clinical recovery occurred in 377 patients in the VV116 group and 378 participants in the nirmatrelvir-ritonavir group. The hazard ratio for the time from randomization to sustained clinical recovery was 1.17 (95% Confidence interval [CI], 1.01 to 1.35). Similar results were reported in sensitivity analyses with the imputation of missing endpoint data (Hazard Ratio, 1.17; 95% CI, 1.01 to 1.35). The median time from randomization to sustain resolution of symptoms was seven days (95% CI, 7 to 8) in both groups. The median time to the first negative SARS-CoV-2 test was seven days in both groups (Hazard Ratio, 0.99; 95% CI, 0.85 to 1.14). Fewer participants in the VV116 group experienced adverse events than in the nirmatrelvir-ritonavir group (67.4% vs. 77.3%). The most common adverse events were dysgeusia, hypertriglyceridemia, and hyperlipidemia. The most serious adverse events were acute cerebral infarction and deterioration of interstitial lung disease in the nirmatrelvir-ritonavir group and repeat positive for SARS-CoV-2 in the VV116 group. In summary, VV116 was noninferior to nirmatrelvir-ritonavir in treating COVID-19 in high-risk patients.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronavirus disease 2019COVID-19COVID-19 Treatmentdeuterated remdesivir hydrobromideinfectious diseaseNirmatrelvir-ritonaviromicronpublic healthSARS-CoV-2VV116
Previous Post

Critical care staff who are spiritual may suffer from increased moral distress

Next Post

Vitamin D effective in preventing the progression of pre-diabetes to diabetes

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

July 10, 2025
Weekly Rewinds

2 Minute Medicine Rewind July 7, 2025

July 10, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Next Post
Vitamin deficiency may persist after Omega-loop gastric bypass

Vitamin D effective in preventing the progression of pre-diabetes to diabetes

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

2-day antibiotic non-inferior to 5-day antibiotic therapy for postoperative management of complex appendectomy

Compliance-linked incentives increase infant immunizations rates in rural India

Maternal COVID-19 vaccination highly effective for conferring immunity to infants

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.